Cell & Gene Therapy Contract Research Organizations Market Size, Industry Growth, 2026-2034
REPORT DETAILS
Cell & Gene Therapy Contract Research Organizations Market Overview
The global cell & gene therapy contract research organizations market size was valued at USD 5.28 billion in 2025. The market is projected to grow at a CAGR of 9.84% from 2026 to 2034. Growth in the market is driven by expanding pipelines of clinical candidates, increasing outsourcing among start-up biotech firms, and stringent regulations and safety standards. The market is also benefiting from the need for specific services in areas such as preclinical development, bioanalytics, clinical operations, recruitment, data management, and follow up.
Market Statistics
Key Takeaways
• North America dominated the market with a 43.0% revenue share in 2025. This dominance is attributed to the robust regulatory frameworks and expedited approval pathways from government agencies.
• The U.S. held the largest revenue share of 86.5% in 2025. The market growth in the country is driven by the growing cancer burden and increasing adoption of advanced cell-based treatments for oncology.
• Asia Pacific is projected to grow at a 10.8% CAGR. This is due to the expanding biotech ecosystems in countries such as China, Japan, South Korea, and Australia.
• The cell therapy segment held the largest market share of 29.0% in 2025. The segment’s leading position is attributed to the rising number of commercialized products and growing adoption of autologous and allogeneic therapeutic approaches.
• The viral vectors segment accounted for the largest share of 56.0% in 2025. This is attributed to the well-established role as delivery systems for both gene therapies and genetically modified cell therapies.
- The clinical operations and monitoring segment accounted for a 38.7% share in 2025. This is owing to the number of cell and gene therapy clinical trials that necessitate expert operations management.
- The lipid nanoparticle segment is anticipated to grow at a 11.2% CAGR. Rising use of mRNA-based treatments has increased applications of lipid nanoparticle technology in cell and gene therapy development.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Cell & Gene Therapy Contract Research Organizations Market Defined
CROs for cell and gene therapy offer services in research and development of advanced therapies such as in vivo gene therapies, gene-modified cell therapies, CAR-T and TCR therapies, and non-gene-modified cell therapies. The common services offered include discovery services, preclinical studies, bioanalysis, regulatory affairs, clinical trials and management, data management, biostatistics, pharmacovigilance, patient recruitment, site selection, real-world evidence, and safety follow up.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
How CGT CRO Services Support the Development Pathway?
Therapy Concept Identification: This begins with identifying a cell/gene therapy concept. It is based on the targeted disease and research goals.
Preclinical Research: This is where CROs perform laboratory studies to examine safety, efficacy, and biological activity of the therapy before moving on to human testing.
Manufacturing Process Development: This involves development of manufacturing processes that include cell processing, viral vectors production, and others.
Clinical Trial Conduct and Management: CROs assist in designing clinical trials, recruitment of patients, managing trials and collecting data during the process.
Regulatory Assistance: They assist in drafting of regulatory documents and working with health agencies as well as helping the sponsor with the approval process.
Therapy Commercialization: This stage comes after successful clinical development and approvals. Here, CROs assist in commercializing the therapy.
Why Companies Outsource Cell & Gene Therapy Development?
Outsourcing the development of cell and gene therapies by biotech and pharma companies to CROs is quite usual to make use of their expertise, technologies, and research personnel for cost savings and shortened development times. Outsourcing contributes to preclinical studies, clinical trials, regulatory affairs, and manufacturing. Moreover, outsourcing helps firms make use of advanced laboratory equipment without making big investments in them. Firms carry out research and innovations while CROs develop them. This outsourcing process has become crucial now when the field of cell and gene therapies is getting increasingly complicated.
CAR-T Therapy Development Support
CROs have been instrumental in the development of CAR-T treatment through their knowledge in cell engineering and modification of immune cells. CROs also help in developing processes of manufacturing, testing, documenting, and monitoring safety during the developmental process. Additionally, CROs are involved in managing clinical trials and manufacturing process optimization to enhance product quality. The expertise of CROs has enabled pharmaceutical companies to develop personalized cancer treatment methods in an efficient manner by overcoming the difficulties of developing such drugs. There will be more demand for CROs that have expertise in advanced oncology treatments due to increased funding for CAR-T treatment development.
Manufacturing & Capacity Expansion
Cell and gene therapy manufacturing needs special facilities and manufacturing processes, along with stringent quality control. The types of services that can be provided by the CROs include GMP manufacturing, viral vector manufacturing, cell processing, quality control, process development, and manufacturing scale-up. All these services help in improving consistency and quality of the products, and help in adhering to regulatory guidelines. In addition, CROs help in optimizing manufacturing operations and increasing manufacturing capacity. With rising demand for advanced therapies, the role of special manufacturing services is growing.
AI Impact on Cell & Gene Therapy Contract Research Organizations Market
- AI provides assistance in analyzing genetic, biomarker, and clinical data to identify eligible patients for the purpose of protocol design for cell and gene therapy trials.
- Machine learning technologies are applied to choose appropriate trial sites, forecast patient recruitment, and plan clinical trials, which allows sponsors to better organize and manage complicated clinical research programs.
- AI-driven clinical data review solutions enhance the quality and consistency of clinical data as well as help to monitor trial safety.
- AI is being used to prepare regulatory documents, integrate research and manufacturing data, and make decisions regarding cell and gene therapy development programs.
The cell & gene therapy contract research organizations (CROs) market is emerging as a key component in the biopharmaceutical R&D ecosystem, offering specialized services to support the complex development needs of advanced therapies. These CROs provide end-to-end solutions, ranging from early-stage discovery and preclinical development to clinical trial execution and regulatory support. The growing need to streamline development timelines, reduce costs, and access global expertise is driving the outsourcing of research functions to CROs with deep technical capabilities in cell and gene therapy modalities.
The demand for specialized contract research organizations (CRO) services in this space is increasing due to the scientific and regulatory complexities involved in developing gene-modified cell therapies, CAR-T cell therapy, and in vivo gene therapies. Cell and gene therapy sponsors are collaborating with CROs to gain access to disease-specific models, biomarkers strategies, and real-world evidence frameworks that accelerate the path from bench to bedside. CROs are also enhancing their infrastructure by investing in GMP-compliant facilities, vector production capabilities, and decentralized trial platforms, catering to the evolving demands of personalized and rare disease therapies.
The growth of the cell & gene therapy CROs market is driven by the increasing investment in regenerative medicine R&D aimed at developing transformative therapies for rare and chronic diseases. The drive among biopharmaceutical companies to deliver first-in-class treatments is fueling a rising demand for specialized external expertise in clinical development, regulatory strategy, and trial execution. Contract research organizations are becoming integral partners in this process, offering technical and operational capabilities tailored to the complex nature of gene-modified cell therapies, in vivo gene therapies, and autologous treatments.
Traditional Drug Development vs. Cell & Gene Therapy Development
| Feature | Traditional Drug Development | Cell & Gene Therapy Development |
| Nature of Treatment | Usually consists of small molecule medicines or biological drugs. | Consists of live cells, DNA/RNA sequences or genetically modified immune cells used as treatment. |
| Process of Development | Consists of standardized research and clinical development process. | Comprises complicated and usually personalized process of development. |
| Production | Usually relies on standard pharmaceutical production techniques. | Comprises unique manufacturing methods that require special GMP facilities, cell processing and viral vectors production. |
| Clinical Trials | Usually follows a standardized design of clinical trials. | Normally includes unique trial design due to rare diseases and personalized therapy. |
| Specialized Expertise | Includes general pharmaceutical research and development skills. | Comprises of unique cell biology, gene editing and immunology expertise. |
| Regulation | Follows standardized drug development pathway. | Includes additional regulation due to complexity of advanced therapies. |
| Scalability | Manufacturing processes are relatively easy to scale for mass production. | Manufacturing processes are complicated to scale due to the unique nature of products. |
Source: Polaris Market Research Analysis
Market Dynamics
Driver: Surge in Public and Private Funding Advancing Gene Editing and Personalized Therapies:
Government and private sector funding in high-impact areas such as gene editing, immunotherapies, and personalized medicine is expanding globally. For example, in March 2025, Arbor Biotechnologies closed a USD 73.9 million Series C financing round to advance its next-generation gene editing therapeutics (source: globenewswire.com). The funds aim to support the clinical development of the lead candidate ABO-101 for primary hyperoxaluria type 1 (PH1), along with other programs targeting liver and CNS diseases, including reverse transcriptase-based editing platforms. This influx of capital is enabling the launch of new development programs, particularly in oncology, rare genetic disorders, and autoimmune conditions. Thus, sponsors are increasingly outsourcing to CROs that provide comprehensive services ranging from biomarker-led trial designs to regulatory submissions and decentralized trial management streamlining the development pathway of advanced therapies.
Driver: Technological Advancements in CRISPR and CAR-T Driving Demand for Specialized CRO Capabilities:
The rapid pace of innovation in enabling technologies such as CRISPR-Cas9 gene editing, viral vector engineering, and CAR-T cell therapies is accelerating the demand for CROs with domain-specific expertise. The intricate scientific, manufacturing, and regulatory requirements of these therapies necessitate partners with deep technical know-how, access to GMP-compliant environments, and a strong understanding of evolving regulatory frameworks. CROs that offer customized solutions aligned with these needs are expediting clinical progress while ensuring safety, efficacy, and compliance across diverse therapy platforms.
Opportunity : Growing Demand for End-to-End Outsourcing Partnerships
As cell and gene therapies become more complex, there is an increased demand for CROs who have the capability to deliver end-to-end development solutions under one contract. Customers require an integrated partner whose service range includes all phases from preclinical testing, clinical testing, regulatory affairs, bioanalysis, manufacturing, to commercialization services. This will solve coordination problems and save time and cost. Such a trend is more common among small biotech organizations lacking required experience and infrastructure. CROs having a wide range of services and global regulatory experience have high chances of developing strategic relationships.
Challenges: Limited Availability of Specialized Talent and Infrastructure
Development of cell and gene-based therapies needs very specific scientific expertise, state-of-the-art manufacturing facilities, and highly-developed laboratory infrastructure. But there is still an insufficient number of experienced specialists in such fields as gene editing, development of viral vectors, cell manufacturing, and regulatory affairs. Additionally, setting up and maintaining GMP-compliant facilities involves high capital expenditures and operating expenses. Such factors may hamper the rapid scaling-up of service provision by CROs in response to increasing customer demand. Smaller players find it more difficult to compete with established providers offering a wider range of capabilities and global infrastructure. It is crucial to tackle the above challenges for sustained growth of the market.
Source: Polaris Market Research Analysis
Segmental Insights
By Service Type Analysis
Based on service type, the market is segmented into discovery and translational research; preclinical services; bioanalytical and assay development; regulatory and CMC consulting; clinical operations and monitoring; data management and biostatistics; pharmacovigilance; patient recruitment and retention; long-term follow-up and real-world evidence. The clinical operations and monitoring segment led with a 38.7% share in 2025. The segment’s dominance is because of the rise in the number of cell and gene therapy clinical trials that necessitate expert operations management, safety monitoring, and compliance issues. Clinical trials in cell and gene therapy are normally complex and require personalization, thus necessitating efficiency in their operations. Sponsors are increasingly outsourcing clinical operations to CROs for better conduct of the trials, quicker patient recruitment, and accurate data gathering from global sites. Adoption of decentralized and hybrid trials is another factor boosting the demand for clinical monitoring services.
By Development Stage analysis
Based on development stage, the market is segmented into discovery, preclinical, phase I, phase II, phase III/pivotal, post-approval, and long-term follow-up. The long-term follow-up segment is projected to grow at a 9.9% CAGR. The regulatory authorities are requiring increasing long-term monitoring of patients receiving cell and gene-based therapies to determine their long-term safety and effectiveness as well as any late adverse effects that may occur. Increasing adoption of gene-engineered and genome editing therapies is fueling the need for long-term monitoring of patients, collection of real-world data, and post-marketing evidence. Contract research organizations offering long-term follow-up, pharmacovigilance, and real-world evidence services are anticipated to benefit from this increasing need.
By Therapy Platform and Delivery Platform Analysis
Based on therapy platform, the market is segmented into in vivo gene therapy, ex vivo gene-modified cell therapy, and non-gene-modified cell therapy. The ex-vivo gene modified cell therapy segment held the largest share of 43.21% in 2025. The leading position of this segment is credited to the increasing use of cell therapies such as CAR-T and other genetically modified cells for treating cancers and rare diseases. Genetically modified cell therapies need complicated processes such as complicated manufacturing process, unique design of clinical studies, and strict regulatory guidelines; thus, creating demand for CRO services during the development, analytical testing, and clinical operations of these therapies.
Based on delivery platform, the market is segmented into AAV, lentiviral/retroviral, adenoviral, lipid nanoparticle, electroporation, and other non-viral delivery. The lipid nanoparticle segment is anticipated to register the highest growth rate of 11.2%. The increasing usage of mRNA-based treatments and the emergence of novel nucleic acid delivery systems are leading to increased applications of lipid nanoparticle technology in cell and gene therapy development. Higher investments in non-viral delivery systems, along with their scalability, reduced immunogenicity, and potential for multiple dosing, will provide new opportunities for CROs working on drug formulation and development.
By Therapeutic Area and Sponsor Type Analysis
By therapeutic area, the market is segmented into oncology; rare/genetic diseases; neurology; autoimmune and inflammatory disorders; cardiovascular; ophthalmology; metabolic disorders; other. The oncology segment held the largest share of 41.2% in 2025. The large market share is owing to the robust pipeline of clinical trials of CAR-T cells, TIL therapy, and genetically modified immunotherapy treatment of hematological and solid tumors.There is increased spending on cancer research and regulatory approvals for innovative oncology drugs, along with more clinical trials. The complexities involved in oncology trials further fuel the demand for such specialized CRO services.
By sponsor type, the market segmentation is based on emerging biotechnology companies; large pharmaceutical and biotechnology companies; academic/nonprofit sponsors; and government and research organizations. The emerging biotechnology companies segment is set to witness the fastest growth rate over the forecast period. Growing venture capital investment, increased innovations in gene and cell therapies, and the growing number of biotech companies in their early stages are boosting the demand for outsourced development services.They use CROs for comprehensive solutions in preclinical testing, clinical development, manufacturing, and submission, thus enabling them to develop new treatments without investing in infrastructure.
Long-Term Follow-Up, Patient Logistics, Site Readiness, and Regulatory Requirements
The clinical trials conducted for cell and gene therapy have distinct logistical complexities that go beyond regular drug discovery trials, and hence the need for special services from CROs. These complexities include the need for extended follow-ups to monitor the sustainability of treatment, possible side effects, and patient safety for many years after the treatment administration. The logistical complexity may be seen in the requirement for coordination of schedules, specialized facilities, and temperature control of patient samples and treatments.
Ensuring site readiness involves training of staff, equipping of trial sites with special equipment and standardized processes for managing advanced therapies. In addition, sponsors must adhere to changing regulations for manufacturing, monitoring, and tracking the source of therapies. CROs assist in streamlining such complex processes in order to facilitate successful execution of clinical trials and commercialization of therapies.
Major Use Cases of Cell & Gene Therapy Contract Research Organizations (CROs)
| Use Case | Description |
| Development of Treatment for Rare Diseases | The use of CROs is beneficial for developing treatments for rare genetic diseases through preclinical research and the conduct of clinical trials for complex treatment programs. |
| Research of Stem Cell Therapy | CROs can help biotech companies develop stem cell therapies by providing cell characterization, manufacturing, quality control, and clinical research services. |
| Research of Gene Editing Technologies | CROs can help biotech companies develop gene-editing therapies through CRISPR-based research, target validation, and preclinical testing. |
| Development of Regenerative Medicine | CROs offer research, manufacturing, and clinical research services for regenerative medicine products that treat tissue damage. |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Regional Analysis
North America accounted for a 43.0% share in 2025. This dominance is attributed to the robust regulatory frameworks and expedited approval pathways from agencies such as the US Food and Drug Administration (FDA) and Health Canada for innovative therapies. The region benefits from substantial public and private funding for clinical trials, particularly in rare diseases and oncology applications. The well-established research infrastructure, coupled with the presence of leading biotechnology hubs, further boosts the market growth in the region.
U.S. Cell & Gene Therapy Contract Research Organizations Market Insights
In 2025, the U.S. held an 86.5% share of the total cell and gene therapy CRO market value in North America. The regional market benefits from its robust advanced therapy pipeline, well-established biotech clusters, competent clinical centers, regulatory proficiency, and demand for outsourcing clinical trial execution. The American Cancer Society projects that there will be an estimated 2,114,850 cases of cancer and 626,140 cancer deaths in the U.S. in 2026, which contributes to the need for oncology trials (source: cancer.org). CROs are being driven by rare disease development, patient recruitment, site preparedness, chain of identity needs, and safety assessment for gene therapy drugs.
Asia Pacific Cell & Gene Therapy Contract Research Organizations Market Trends
The market in Asia Pacific is projected to grow at a 10.8% CAGR due to the expanding biotech ecosystems in countries such as China, Japan, South Korea, and Australia. Government-backed initiatives and favorable regulatory frameworks are promoting advanced therapy research and development. Also, increasing investments in infrastructure and the emergence of regionally based CROs with global-standard capabilities are further boosting market growth.
India Cell & Gene Therapy Contract Research Organizations Market Overview
The market in India is projected to grow at a 12.4% CAGR. India is emerging as a major hub for cellular and gene therapy research services as a result of its growing biotechnology landscape, clinical capabilities, and scientific expertise. According to PIB data, the country’s bioeconomy stood at USD 165.7 billion in 2024 and is projected to reach USD 300 billion in 2030 (source: pib.gov.in). In the context of the CRO industry, the major areas of relevance include preclinical research, bioanalytical services, regulatory services, clinical operations, data management, and availability of specialized investigator networks.
Europe Cell & Gene Therapy Contract Research Organizations Market Assessments
Europe accounted for a 28.6% share in 2025. Europe continues to be a significant region for research into cell and gene therapies owing to the advanced scientific base, well-developed ATMPs structure, academic community, and clinical centers' specialization. According to EFPIA, the pharmaceutical industry invested about EUR 60.0 billion in R&D in Europe in 2025 (source: efpia.eu). The CRO market growth is driven by multinational trial needs, EMA recommendations, GMO and biosafety applications, rare diseases research networks, and coordination of quality, clinical and post-trial follow-up processes.
Source: Polaris Market Research Analysis
Key Players & Competitive Analysis
The global cell & gene therapy contract research organizations (CROs) market is highly competitive. Competition includes global, full service CROs; specialized, biotech-focused CROs; regional clinical research facilities; bioanalytical laboratories; and regulatory consultancy companies. Direct CGT competitors include organizations with proven ability in advanced-therapy study designs, rare disease patient recruitment, site qualifying, logistics, regulatory strategy, bioanalytics, and follow-up.
The market is experiencing a growing emphasis on decentralized and hybrid clinical trial models, driven by the unique logistics and patient recruitment challenges associated with advanced therapies. Companies are increasingly investing in specialized manufacturing support, real-world evidence generation, and regulatory navigation for accelerated approvals. Strategic collaborations, mergers, and acquisitions remain common approaches to expand service offerings and geographical reach, while competition intensifies in emerging markets where cell and gene therapy pipelines are rapidly expanding.
| Segment | Companies |
| Large Global Full-Service CROs | ICON, Parexel, Fortrea, PPD Clinical Research Business, Syneos Health, Medpace |
| Specialty and Biotech-Focused CROs | Allucent, Altasciences, Novotech, Avance Clinical, Linical, QPS, Aixial Group |
| Asia-Focused and Integrated Providers | CMIC Group, Syngene International |
| Regulatory and Lifecycle Consulting | PharmaLex/Cencora |
| Laboratory and Bioanalytical Providers | Labcorp, Other Specialist Laboratories |
List of Key Companies
- Altasciences
- Allucent
- Aixial Group
- CMIC Group
- ICON plc
- Fortrea
- Linical
- Medpace, Inc.
- Novotech
- PharmaLex (Part of Cencora)
- PPD (Thermo Fisher Scientific, Inc.)
- Precision for Medicine
- QPS Holdings, LLC
- Syneos Health, Inc.
- Syngene International Limited (included as a CRO)
- Parexel
- Avance Clinical
Future Outlook
The market for cell & gene therapy contract research organizations (CROs) will experience steady growth as global development of advanced therapies expands. Increased investments in cell and gene therapies, the rise in the use of personalized medicines, and the growing demand for specialized services in research and manufacturing will drive market growth. Innovations in CAR-T therapy, gene-editing tools, and regenerative medicine will create new opportunities for CROs with specific knowledge and skills. On the other hand, the growing number of clinical trials and changing regulations will make biotech and pharmaceutical companies consider outsourcing their projects to CROs. Innovation in advanced therapies will further advance the development of CROs.
Cell & Gene Therapy Contract Research Organizations Industry Developments
- January 2026: Avance Clinical announced the acquisition of LumaBridge, a specialized U.S.-based clinical CRO with deep expertise in oncology trials. According to Avance Clinical, the acquisition will expand the company’s existing presence in the U.S. It marks a major milestone in accelerating the company’s growth in oncology. (source: avancecro.com)
- January 2026: WEP Clinical (WEP) announced the acquisition of Netherlands-based European CRO, Siron Clinical (Siron). According to WEP, the acquisition will expand its global footprint. It will also strengthen the company’s ability to deliver end-to-end Phase I–IV clinical trial solutions across complex and specialized therapeutic areas. (source: wepclinical.com)
Cell & Gene Therapy Contract Research Organizations Market Segmentation
By Service Type Outlook (Revenue, USD Billion, 2021–2034)
- Discovery and Translational Research
- Preclinical Services
- Bioanalytical and Assay Development
- Regulatory and CMC Consulting
- Clinical Operations and Monitoring
- Data Management and Biostatistics
- Pharmacovigilance
- Patient Recruitment and Retention
- Long-Term Follow-Up and Real-World Evidence
By Development Stage Outlook (Revenue, USD Billion, 2021–2034)
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III/pivotal
- Post-Approval
- Long-Term Follow-Up
By Therapy Platform Outlook (Revenue, USD Billion, 2021–2034)
- In Vivo Gene Therapy
- Ex Vivo Gene-Modified Cell Therapy
- CAR-T
- TCR
- Other Engineered Cells
- Non-Gene-Modified Cell Therapy
- Stem Cells
By Delivery Platform Outlook (Revenue, USD Billion, 2021–2034)
- AAV
- Lentiviral/Retroviral
- Adenoviral
- Lipid Nanoparticle
- Electroporation
- Other Non-Viral Delivery
By Therapeutic Area Outlook (Revenue, USD Billion, 2021–2034)
- Oncology
- Rare/Genetic Diseases
- Neurology
- Autoimmune and Inflammatory Disorders
- Cardiovascular
- Ophthalmology
- Metabolic Disorders
- Other
By Sponsor Type Outlook (Revenue, USD Billion, 2021–2034)
- Emerging Biotechnology Companies
- Large Pharmaceutical and Biotechnology Companies
- Academic/Nonprofit Sponsors
-
Government and Research Organizations
By Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Cell & Gene Therapy Contract Research Organizations Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 5.28 Billion |
| Market Size in 2026 | USD 5.79 Billion |
| Revenue Forecast by 2034 | USD 12.29 Billion |
| CAGR | 9.84% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Cell & Gene Therapy Contract Research Organizations Market FAQ's
The global market size was valued at USD 5.28 billion in 2025 and is projected to grow to USD 12.29 billion by 2034.
The global market is projected to register a CAGR of 9.84% during the forecast period.
North America led with a 43.0% revenue share in 2025. This dominance is attributed to the robust regulatory frameworks and expedited approval pathways from government agencies.
A few of the key market players include Altasciences, Allucent, Aixial Group, CMIC Group, ICON plc, Fortrea, Linical, Medpace, Inc., Novotech, PharmaLex (Part of Cencora), PPD (Thermo Fisher Scientific, Inc.), Precision for Medicine, QPS Holdings, LLC, Syneos Health, Inc., Syngene International Limited, Parexel, and Avance Clinical.
The clinical operations and monitoring segment accounted for a 38.7% share in 2025. This is owing to the number of cell and gene therapy clinical trials that necessitate expert operations management.
The lipid nanoparticle segment is anticipated to grow at a 11.2% CAGR. Rising use of mRNA-based treatments has increased applications of lipid nanoparticle technology in cell and gene therapy development.
The services provided by cell and gene therapy CROs include research, clinical trial assistance, manufacturing, regulatory assistance, and testing. They provide the necessary expertise and services to facilitate the development of the products.
CROs contribute to the development of cell and gene therapies through their expertise, facilities, and research. In addition, they facilitate the development of cell and gene therapy products.
There has been an increased demand for CROs in this market owing to the increased investments being made in cell and gene therapy as well as personalized medicines.
Download Sample Report of Cell & Gene Therapy Contract Research Organizations Market
Please fill out the form to request a customized copy of the research report.
